Hydromorphone Hydrochloride

Synopsis, Chemistry

APIs // Active Pharmaceutical Ingredients

20 Suppliers, 12 USDMF, 6 CEP/COS, 1 JDMF, 2 KDMF, 24 NDC API, 9 Listed Suppliers

PRICE INFORMATION

API Reference Price

API Reference Price

DOSSIERs // Finished Dosage Forms

223 Dossiers, 75 FDA Orange Book, 45 Europe, 43 Canada, 37 Australia, 5 South Africa, 18 Listed Dossiers

DRUG PRODUCT COMPOSITION

INJECTABLE;INJECTION - 0.2MG/ML, INJECTABLE;INJECTION - 0.5MG/0.5ML, INJECTABLE;INJECTION - 10MG/ML, INJECTABLE;INJECTION - 1MG/ML, INJECTABLE;INJECTION - 2MG/ML, INJECTABLE;INJECTION - 4MG/ML, SOLUTION;ORAL - 5MG/5ML, TABLET;ORAL - 2MG, TABLET;ORAL - 4MG, TABLET;ORAL - 8MG, TABLET, EXTENDED RELEASE;ORAL - 12MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, TABLET, EXTENDED RELEASE;ORAL - 16MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, TABLET, EXTENDED RELEASE;ORAL - 32MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, TABLET, EXTENDED RELEASE;ORAL - 8MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

RELATED EXCIPIENT COMPANIES

Suppliers, 39 Kerry, 26 BASF, 24 Roquette, 17 Microlex e.U, 14 SPI Pharma, 12 Corel Pharma Chem, 12 Seppic, 11 Gangwal Healthcare, 11 Actylis, 11 Sigachi Industries, 11 Gangwal Chemicals, 8 Nanjing Well Pharmaceutical, 7 Ideal Cures Pvt Ltd, 6 Anhui Sunhere Pharmaceutical Excipients Co.,Ltd, 6 Lonza Capsugel, 6 DFE Pharma, 5 Shanghai Shenmei Pharmaceutical Technology Co., Ltd, 4 DKSH, 4 Boai NKY Pharmaceuticals Ltd, 3 Kima Chemical, 3 Pharmatrans-Sanaq, 3 Prachin Chemical, 3 Pfanstiehl, 3 Vasa Pharmachem, 2 Nomisma Healthcare, 2 The Dow Chemical Company, 2 Shijiazhuang Huaxu Pharmaceutical, 2 Rochem International Inc, 2 Ingredion Pharma Solutions, 2 Seqens, 2 Finar, 2 Ulanqab Kema New Material, 1 ACG Worldwide, 1 Jai Radhe Sales, 1 Zhejiang Huakang Pharmaceutical, 1 Qianhao Chemical (Hebei) Co., Ltd, 1 Qualicaps, 1 Clariant, 1 Aeon Procare, 1 Evonik, 1 Shanghai Welltone Material Technology Co., Ltd, 1 Alcedo Pharmachem, 1 Huzhou Sunflower Pharmaceutical Co. Ltd, 1 Vertellus, 1 Nanjing Bold Chemical

EXCIPIENTS BY APPLICATIONS

87 Fillers, Diluents & Binders, 54 Coating Systems & Additives, 38 Direct Compression, 36 Controlled & Modified Release, 27 Solubilizers, 26 Parenteral, 26 Film Formers & Plasticizers, 24 Granulation, 24 Thickeners and Stabilizers, 20 Disintegrants & Superdisintegrants, 19 Taste Masking, 19 Lubricants & Glidants, 17 Co-Processed Excipients, 16 Topical, 13 Chewable & Orodispersible Aids, 8 API Stability Enhancers, 6 Emulsifying Agents, 5 Empty Capsules, 4 Vegetarian Capsules, 4 Surfactant & Foaming Agents, 4 Rheology Modifiers, 2 Coloring Agents, 1 Soft Gelatin

GLOBAL SALES INFORMATION

44 US Medicaid Prescriptions, 50 Finished Drug Prices

MARKET PLACE

1 APIs, 2 DOSSIERS // FDF

PATENTS

14 US Patents, 12 Health Canada Patents

ANALYTICAL SOLUTION(s)

2 EDQM Standards, 3 USP Standards, 5 Other Ref. Standards

DIGITAL CONTENT

57 News

57 News

Information, Expiry & Status of Health Canada Patents covering Hydromorphone Hydrochloride.

Hydromorphone Hydrochloride

Synopsis

Chemistry

APIs // Active Pharmaceutical Ingredients

20 Suppliers

12 USDMF

6 CEP/COS

1 JDMF

2 KDMF

24 NDC API

9 Listed Suppliers

PRICE INFORMATION

API Reference Price

DOSSIERs // Finished Dosage Forms

223 Dossiers

75 FDA Orange Book

45 Europe

43 Canada

37 Australia

5 South Africa

18 Listed Dossiers

DRUG PRODUCT COMPOSITION

INJECTABLE;INJECTION - 0.2MG/ML

INJECTABLE;INJECTION - 0.5MG/0.5ML

INJECTABLE;INJECTION - 10MG/ML

INJECTABLE;INJECTION - 1MG/ML

INJECTABLE;INJECTION - 2MG/ML

INJECTABLE;INJECTION - 4MG/ML

SOLUTION;ORAL - 5MG/5ML

TABLET;ORAL - 2MG

TABLET;ORAL - 4MG

TABLET;ORAL - 8MG

TABLET, EXTENDED RELEASE;ORAL - 12MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

TABLET, EXTENDED RELEASE;ORAL - 16MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

TABLET, EXTENDED RELEASE;ORAL - 32MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

TABLET, EXTENDED RELEASE;ORAL - 8MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

RELATED EXCIPIENT COMPANIES

Suppliers

39 Kerry

26 BASF

24 Roquette

17 Microlex e.U

14 SPI Pharma

12 Corel Pharma Chem

12 Seppic

11 Gangwal Healthcare

11 Actylis

11 Sigachi Industries

11 Gangwal Chemicals

8 Nanjing Well Pharmaceutical

7 Ideal Cures Pvt Ltd

6 Anhui Sunhere Pharmaceutical Excipients Co.,Ltd

6 Lonza Capsugel

6 DFE Pharma

5 Shanghai Shenmei Pharmaceutical Technology Co., Ltd

4 DKSH

4 Boai NKY Pharmaceuticals Ltd

3 Kima Chemical

3 Pharmatrans-Sanaq

3 Prachin Chemical

3 Pfanstiehl

3 Vasa Pharmachem

2 Nomisma Healthcare

2 The Dow Chemical Company

2 Shijiazhuang Huaxu Pharmaceutical

2 Rochem International Inc

2 Ingredion Pharma Solutions

2 Seqens

2 Finar

2 Ulanqab Kema New Material

1 ACG Worldwide

1 Jai Radhe Sales

1 Zhejiang Huakang Pharmaceutical

1 Qianhao Chemical (Hebei) Co., Ltd

1 Qualicaps

1 Clariant

1 Aeon Procare

1 Evonik

1 Shanghai Welltone Material Technology Co., Ltd

TABLET, EXTENDED RELEASE;ORAL - 12MG Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

TABLET, EXTENDED RELEASE;ORAL - 16MG Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

TABLET, EXTENDED RELEASE;ORAL - 32MG Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

TABLET, EXTENDED RELEASE;ORAL - 8MG Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons